Clinical trial
A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT03690154 is registered in ClinicalTrials.gov with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multi-center, Open-label, Single-arm, Dose-escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Lead sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 23, 2018
- Completion date
- February 11, 2022
- Enrollment
- 67 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia refractory, acute myeloid leukemia, in relapse, advanced cancer, solid tumors